These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23201151)

  • 1. Risk factors and treatment outcome of ertapenem non-susceptible enterobacteriaceae bacteraemia.
    Marimuthu K; Ng TM; Teng C; Lim TP; Koh TH; Tan TY; Krishnan PU; Lye D
    J Infect; 2013 Mar; 66(3):294-6. PubMed ID: 23201151
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-treatment of carbapenemase-producing Enterobacteriaceae.
    Rihani DS; Wallace MR; Sieger BE; Waite RA; Fox M; Brown SA; Deryke CA
    Scand J Infect Dis; 2012 May; 44(5):325-9. PubMed ID: 22200121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-Lactams without a suicide inhibitor.
    Giamarellou H
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of extended-spectrum beta-lactamases.
    Rodríguez-Baño J; Pascual A
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):671-83. PubMed ID: 18847405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia.
    Lye DC; Wijaya L; Chan J; Teng CP; Leo YS
    Ann Acad Med Singap; 2008 Oct; 37(10):831-4. PubMed ID: 19037516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intra-abdominal infections at five medical centers in Taiwan, 2006-2010.
    Ho CM; Ho MW; Liu YC; Toh HS; Lee YL; Liu YM; Huang CC; Lu PL; Liu CE; Chen YH; Ko WC; Tang HJ; Yu KW; Chen YS; Chuang YC; Wang JH; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S24-8. PubMed ID: 22749055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-spectrum beta-lactamase-producing Enterobacteriaceae at Middlemore Hospital.
    Briggs S; Ussher J; Taylor S
    N Z Med J; 2005 Jul; 118(1218):U1563. PubMed ID: 16027752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ertapenem-resistant Enterobacteriaceae: risk factors for acquisition and outcomes.
    Hyle EP; Ferraro MJ; Silver M; Lee H; Hooper DC
    Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1242-9. PubMed ID: 21029005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study.
    Liu SW; Chang HJ; Chia JH; Kuo AJ; Wu TL; Lee MH
    J Microbiol Immunol Infect; 2012 Apr; 45(2):113-9. PubMed ID: 22154994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca at the Radboud University Nijmegen Medical Centre in The Netherlands.
    Sturm PD; Bochum ET; van Mook-Vermulst SV; Handgraaf C; Klaassen T; Melchers WJ
    Microb Drug Resist; 2010 Mar; 16(1):55-60. PubMed ID: 20001741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.
    Stainton SM; Thabit AK; Kuti JL; Aslanzadeh J; Nicolau DP
    Clin Microbiol Infect; 2017 Aug; 23(8):581-582. PubMed ID: 28254605
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Collins VL; Marchaim D; Pogue JM; Moshos J; Bheemreddy S; Sunkara B; Shallal A; Chugh N; Eiseler S; Bhargava P; Blunden C; Lephart PR; Memon BI; Hayakawa K; Abreu-Lanfranco O; Chopra T; Munoz-Price LS; Carmeli Y; Kaye KS
    Antimicrob Agents Chemother; 2012 Apr; 56(4):2173-7. PubMed ID: 22290982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
    Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
    Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.